• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Topoisomerase I Inhibitor
    5 Drugs classified under this drug class


    All the Drug Class Drugs

    Campto
    Pfizer
    RX
    partial basket chart
    Campto

    Topoisomerase I Inhibitor. Irinotecan HCl 20 mg/ml.
    CONC. FOR INFUS: 2 ml x 40 mg; 5 ml x
    100 mg, 15 ml x 300 mg. Dosage should
    be ajust. individ.
    Tmt. of pts. with metastat. colorect.
    cancer:
    In comb. with 5-FU and folinic
    acid in pts. without prior chemother. for
    metastat. dis.
    As a single agent in pts. who have failed
    an established 5-FU contain.
    tmt. regimen.
    Tmt. of pts. with small cell lung canerc.
    Tmt. of pts. with gastr. cancer.
    Irinotecan in comb. with leucovorin and
    5-FU for the first line
    tmt. of pts. with metastatic pancreat.
    adenocarcinoma.
    C/I: Hypersens.
    Chron. IBD and/or bowel obstruct.
    Lact.
    Bilirubin > 3 times the upper limit of the
    normal range.
    Severe bone marrow fail.
    WHO performance status > 2.
    Concom. use with St John’s Wort.
    Live attenuat. vaccin.

    Hycamtin Capsules
    Novartis
    RX
    partial basket chart
    Hycamtin Capsules

    Topoisomerase I Inhibitor. Topotecan HCl 0.25 mg, 1 mg.
    HARD CAPS: 10 x 0.25 mg, 1 mg. See lit.
    Tmt. pts with relapsed small cell lung
    cancer (SCLC) when re-tmt. with first-line
    regimen not approp.
    C/I: Severe hypersens., pregn., lact.,
    severe bone marrow depress. prior to
    start. 1st course (baseline neutrophils
    less than 1.5 x 10^9/L and/or placelet
    count less than 100 x 10^9/L.

    Hycamtin IV
    Novartis
    RX
    partial basket chart
    Hycamtin IV

    Topoisomerase I Inhibitor. Topotecan HCl 4 mg.
    VIAL (for infusion): 1. Dose must adjust.
    accord. to indication, blood counts and
    pt’s medical condit. See it.
    Metastat. carcinoma ovary where 1st -line
    or subsequent ther. failed, small cell lung
    cancer sens. dis. aft. fail. first line chemo.
    In comb. with cisplatin: Stage IV-B recur./
    persist. carcinoma cervix not amenable to
    curative tmt. with surg. and/or radiat.
    ther.
    C/I: Hypersens., lact., pts. already have
    severe bone marrow depress. prior to
    starting 1st course, as evidenced by
    baseline neutrophils < 1.5 x 109/l and/
    or a platelet count of <100 x 109/l.

    Irinotecan Actavis 20 mg/ml
    Abic
    RX
    partial basket chart
    Irinotecan Actavis 20 mg/ml

    Topoisomerase I Inhibitor. Irinotecan HCl Trihydrate 20 mg/ml.
    GLASS VIAL(Concent.  for sol. for IV infus.): 1×5,15, 25 ml. Dosage must be ajust. individ.
    For the tmt. of patients with metastat. colorect. canc.: In comb.with 5-fluorouracil & folinic acid in pts. without prior chemother. for metastat. dis.
    As a single agent in pts. who have failed an establish. 5-fluorouracil contain. tmt regimen.
    For the tmt. of pts. with small cell lung canc.
    For the tmt. of pts. with gastric canc.
    C/I: Hypersens. Chron. inflamm.  bowel dis.  and/or bowel obstruct. Pregn. and lact. Bilirubin > 3 times the ULN. Severe  bone marrow fail. WHO performance status > 2. Concomit. use with St John's Wort.

    Irinotecan Injection
    Pfizer
    RX
    partial basket chart
    Irinotecan Injection

    Topoisomerase I Inhibitor. Irinotecan HCl 20 mg/ml.
    CONC. FOR INFUS: 2 ml x 40 mg; 5 ml x
    100 mg, 25 ml x 500 mg. See lit.
    Metastat. colorectal cancer either in comb.
    with 5-fluorouracil and folinic acid in
    patients without prior chemother. for
    metastat. dis., or as single agent in pts.
    who have failed an established
    5-fluorouracil cont. tmt. regimen. Small
    cell lung cancer, gastric cancer.
    C/I: Chron. inflamm. bowel dis. and/or
    bowel obstruct., hypersens., pregn., lact.,
    bilirubin >3 times the upper limit of the
    normal range, severe bone marrow
    failure, WHO performance status > 2,
    concom. use with St. John’s wort.

    CLOSE